Zeitschriftenartikel zum Thema „He53“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "He53" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.
Kent, Matthew R., Delia Calderon, Katherine M. Silvius, Jack P. Kucinski, Collette A. LaVigne, Matthew V. Cannon und Genevieve C. Kendall. „Abstract 3533: Zebrafish her3 knockout impacts developmental and rhabdomyosarcoma-related gene signatures“. Cancer Research 83, Nr. 7_Supplement (04.04.2023): 3533. http://dx.doi.org/10.1158/1538-7445.am2023-3533.
Der volle Inhalt der QuelleBeckford Vera, Denis, Jason Li, Le-Cun Xu, Debbie Lewis, Amanda Chin, Patrik Brodin, Mary Chen, Monideepa Roy und Helen Kotanides. „Preclinical evaluation of novel HER3-targeting radioconjugates for the imaging and treatment of HER3-expressing cancers.“ Journal of Clinical Oncology 41, Nr. 16_suppl (01.06.2023): e15114-e15114. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e15114.
Der volle Inhalt der QuelleKoyama, Kumiko, Hirokazu Ishikawa, Manabu Abe, Yoshinobu Shiose, Suguru Ueno, Yang Qiu, Kenji Nakamaru und Masato Murakami. „Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression“. PLOS ONE 17, Nr. 5 (03.05.2022): e0267027. http://dx.doi.org/10.1371/journal.pone.0267027.
Der volle Inhalt der QuelleKomatsu, Nagiho, Saori Sato, Sumie Muramatsu, Ryuichi Nakamura und Kumiko Koyama. „Abstract 3996: The impact of HER3 dynamics on the efficacy of HER3-DXd, a novel HER3 directed antibody-drug conjugate“. Cancer Research 83, Nr. 7_Supplement (04.04.2023): 3996. http://dx.doi.org/10.1158/1538-7445.am2023-3996.
Der volle Inhalt der QuelleO'Hare, Thomas, Jaclyn Cleveland, Valerie M. Jansen und David Dornan. „Abstract 3121: Therapeutic potential of a HER3 antibody-drug conjugate for the treatment of HER3-expressing cancers“. Cancer Research 84, Nr. 6_Supplement (22.03.2024): 3121. http://dx.doi.org/10.1158/1538-7445.am2024-3121.
Der volle Inhalt der QuelleBeckford-Vera, Denis, Megan McCloskey, Jason Li, Caroline Jennings, Le-Cun Xu, Debbie Lewis, Patrik Brodin et al. „Abstract 5040: Novel HER3 targeting antibody radioconjugates, 225Ac-HER3 ARC and 177Lu-HER3 ARC, exhibit potent antitumor efficacy in HER3-positive solid tumors“. Cancer Research 83, Nr. 7_Supplement (04.04.2023): 5040. http://dx.doi.org/10.1158/1538-7445.am2023-5040.
Der volle Inhalt der QuelleToy, Weiyi, Dipti Thakkar, Roberto Magallanes, Sharon Wu, Ming Poi, Alejandro Mas, Konrad Paszkiewicz, Piers Ingram und Jerome Boyd-Kirkup. „Abstract 5796: A HER3 antibody that uniquely blocks the HER3 heterodimerization interface effectively inhibits tumor growth in pre-clinical models with potentially oncogenic HER3 mutations“. Cancer Research 84, Nr. 6_Supplement (22.03.2024): 5796. http://dx.doi.org/10.1158/1538-7445.am2024-5796.
Der volle Inhalt der QuelleBeckford-Vera, Denis, Jason Li, Megan McCloskey, Caroline Jennings, Amanda Chin, Qing Liang, Jesse Hwang, Monideepa Roy, Mary Chen und Helen Kotanides. „Abstract 3306: Targeting HER3 receptor positive cancers with a novel anti-HER3 antibody radioconjugate (ARC)“. Cancer Research 82, Nr. 12_Supplement (15.06.2022): 3306. http://dx.doi.org/10.1158/1538-7445.am2022-3306.
Der volle Inhalt der QuelleScartozzi, M., A. Mandolesi, R. Giampieri, A. Zaniboni, E. Galizia, L. Giustini, R. R. Silva, R. Berardi, I. Bearzi und S. Cascinu. „The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan/cetuximab.“ Journal of Clinical Oncology 29, Nr. 4_suppl (01.02.2011): 404. http://dx.doi.org/10.1200/jco.2011.29.4_suppl.404.
Der volle Inhalt der QuelleMartinez Lago, Nieves, Ihab Abdulkader, Dora Insua Santamaria, Patricia Viaño Nuñez, Juan Jose Carrera, Jose Ramón Antunez Lopez, Maria Elena Padin Iruegas und Rafael López López. „Assessment and prognostic impact of a new classification using HER2 and HER3 status in resected gastric cancer in a european cohort.“ Journal of Clinical Oncology 36, Nr. 4_suppl (01.02.2018): 65. http://dx.doi.org/10.1200/jco.2018.36.4_suppl.65.
Der volle Inhalt der QuelleMukherjee, Sumit, Debbie Lewis, Jason Li, Le-Cun Xu, Amanda Chin, Mary Chen, Monideepa Roy et al. „Abstract A149: Characterization of HER3 targeted radioligand therapy using molecular imaging“. Molecular Cancer Therapeutics 22, Nr. 12_Supplement (01.12.2023): A149. http://dx.doi.org/10.1158/1535-7163.targ-23-a149.
Der volle Inhalt der QuelleXie, Xuemei, Jangsoon Lee, Jon A. Fuson, Huey Liu, Young Jin Gi, Pang-Dian Fan, Kumiko Koyama, Debu Tripathy und Naoto T. Ueno. „Abstract LB088: Targeting ATR enhances the antitumor efficacy of patritumab deruxtecan (HER3-DXd) in tamoxifen-resistant ER+ breast cancer cells by reprogramming cell cycle progression“. Cancer Research 82, Nr. 12_Supplement (15.06.2022): LB088. http://dx.doi.org/10.1158/1538-7445.am2022-lb088.
Der volle Inhalt der QuelleBeckford-Vera, Denis, Jason Li, Caroline Jennings, Megan McCloskey, Amanda Chin, Qing Liang, Jesse Hwang, Monideepa Roy, Mary Chen und Helen Kotanides. „Abstract 609: Anti-HER3 radioimmunotherapy enhances the anti-tumor effects of CD47 blockade in solid tumors“. Cancer Research 82, Nr. 12_Supplement (15.06.2022): 609. http://dx.doi.org/10.1158/1538-7445.am2022-609.
Der volle Inhalt der QuelleChang, Chi-Son, Jung In Shim, Sun-Ju Byeon, Eun Jin Lee, Yoo-Young Lee, Tae-Joong Kim, Jeong-Won Lee, Byoung-Gie Kim und Chel Hun Choi. „Prognostic Significance of HER3 Expression in Patients with Cervical Cancer“. Cancers 14, Nr. 9 (25.04.2022): 2139. http://dx.doi.org/10.3390/cancers14092139.
Der volle Inhalt der QuelleChang, Chi-Son, Jung In Shim, Sun-Ju Byeon, Eun Jin Lee, Yoo-Young Lee, Tae-Joong Kim, Jeong-Won Lee, Byoung-Gie Kim und Chel Hun Choi. „Prognostic Significance of HER3 Expression in Patients with Cervical Cancer“. Cancers 14, Nr. 9 (25.04.2022): 2139. http://dx.doi.org/10.3390/cancers14092139.
Der volle Inhalt der QuelleAmin, Dhara N., Natalia Sergina, Lionel Lim, Andrei Goga und Mark M. Moasser. „HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells“. Biochemical Journal 447, Nr. 3 (05.10.2012): 417–25. http://dx.doi.org/10.1042/bj20120724.
Der volle Inhalt der QuelleRajendran, Rithika, Coen Johannes Gerardus Lap, Fayez Estephan, Shanshan Liu, Ramesh Subrahmanyam, Guoqing Diao, Victor Nava und Maneesh Rajiv Jain. „Prevalence of HER3 expression in prostate adenocarcinoma and its clinicopathological characteristics.“ Journal of Clinical Oncology 42, Nr. 16_suppl (01.06.2024): 5019. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.5019.
Der volle Inhalt der QuelleYonesaka, Kimio, Junko Tanizaki, Osamu Maenishi, Koji Haratani, Hisato Kawakami, Kaoru Tanaka, Hidetoshi Hayashi et al. „Dynamics of HER3 and its correlated gene expression profile in EGFR-mutated NSCLC tumor treated with EGFR-TKI toward enhancing effectiveness of patritumab deruxtecan (HER3-DXd; U3-1402).“ Journal of Clinical Oncology 40, Nr. 16_suppl (01.06.2022): e21175-e21175. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e21175.
Der volle Inhalt der QuelleYonesaka, Kimio, Junko Tanizaki, Osamu Maenishi, Koji Haratani, Hisato Kawakami, Kaoru Tanaka, Hidetoshi Hayashi et al. „Dynamics of HER3 and its correlated gene expression profile in EGFR-mutated NSCLC tumor treated with EGFR-TKI toward enhancing effectiveness of patritumab deruxtecan (HER3-DXd; U3-1402).“ Journal of Clinical Oncology 40, Nr. 16_suppl (01.06.2022): e21175-e21175. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e21175.
Der volle Inhalt der QuelleKim, Joori, Jeong-Oh Kim, Youn Soo Lee, Jung-Young Shin, Min Young Kim, Mi-Ran Lee, Seoree Kim et al. „The changes of HER3 expression in head and neck cancer patients treated with induction chemotherapy.“ Journal of Clinical Oncology 41, Nr. 16_suppl (01.06.2023): e18004-e18004. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e18004.
Der volle Inhalt der QuelleMishra, Rosalin, Mary Kate Kilroy, Wasim Feroz, Hima Patel, Samar Alanazi und Joan T. Garrett. „Abstract 3916: role of her3 v104l mutation on tumor growth and her3 stabilization“. Cancer Research 83, Nr. 7_Supplement (04.04.2023): 3916. http://dx.doi.org/10.1158/1538-7445.am2023-3916.
Der volle Inhalt der QuelleÒdena, Andreu, Laia Monserrat, Fara Brasó-Maristany, Marta Guzmán, Judit Grueso, Olga Rodríguez, Maurizio Scaltriti et al. „Abstract P5-13-14: Antitumor activity of patritumab deruxtecan (HER3-DXd), a HER3-directed antibody drug conjugate (ADC) across a diverse panel of breast cancer (BC) patient-derived xenografts (PDXs)“. Cancer Research 82, Nr. 4_Supplement (15.02.2022): P5–13–14—P5–13–14. http://dx.doi.org/10.1158/1538-7445.sabcs21-p5-13-14.
Der volle Inhalt der QuelleManickavasagar, Thubeena, Wei Yuan, Suzanne Carreira, Bora Gurel, Susana Miranda, Ana Ferreira, Mateus Crespo et al. „HER3 expression and MEK activation in non-small-cell lung carcinoma“. Lung Cancer Management 10, Nr. 2 (Juni 2021): LMT48. http://dx.doi.org/10.2217/lmt-2020-0031.
Der volle Inhalt der QuelleRathore, Moeez Ghani, Wei Zhang, Michel'le Wright, Jordan Winter, Yamu Li, Zhenghe Wang und Rui Wang. „Abstract 3177: Liver endothelium secreted LRG1 is a novel ligand of HER3 to promote metastatic colorectal cancer growth“. Cancer Research 82, Nr. 12_Supplement (15.06.2022): 3177. http://dx.doi.org/10.1158/1538-7445.am2022-3177.
Der volle Inhalt der QuelleNishioka, Mariko, Chigusa Morizane, Mao Okada, Tomoyuki Satake, Nobuyoshi Hiraoka, Satoshi Nara, Tomoya Kakegawa et al. „HER3 expression status following systemic chemotherapy treatment in biliary tract cancers.“ Journal of Clinical Oncology 41, Nr. 16_suppl (01.06.2023): e16153-e16153. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e16153.
Der volle Inhalt der QuelleXie, Xuemei, Jangsoon Lee, Jon A. Fuson, Huey Liu, Young J. Gi, Thanasis Poullikkas, Pang-Dian Fan, Kumiko Koyama, Debu Tripathy und Naoto T. Ueno. „Abstract LB042: Targeting ATR enhances the antitumor efficacy of patritumab deruxtecan (HER3-DXd)in tamoxifen-resistant ER+ breast cancer cells by inducing DNA damage and apoptosis“. Cancer Research 83, Nr. 8_Supplement (14.04.2023): LB042. http://dx.doi.org/10.1158/1538-7445.am2023-lb042.
Der volle Inhalt der QuelleKilroy, Mary Kate, SoYoung Park, Wasim Feroz, Hima Patel, Rosalin Mishra, Samar Alanazi und Joan T. Garrett. „HER3 Alterations in Cancer and Potential Clinical Implications“. Cancers 14, Nr. 24 (14.12.2022): 6174. http://dx.doi.org/10.3390/cancers14246174.
Der volle Inhalt der QuelleMishra, Rosalin, Mary Kate Kilroy, Hima Patel, Samar Alanazi und Joan T. Garrett. „Abstract 5412: Role of her3 mutations on breast cancer oncogenesis“. Cancer Research 82, Nr. 12_Supplement (15.06.2022): 5412. http://dx.doi.org/10.1158/1538-7445.am2022-5412.
Der volle Inhalt der QuelleHwang, Hae Min, So Hyeon Kim, Sujin Ham, Minyoung Lee, Youlim Noh, Yu-Jin Kim, Changyun Lee et al. „Abstract C120: Antitumor effect of HER3-DXd, an antibody-drug conjugate targeting HER3, in gastric cancer cell lines“. Molecular Cancer Therapeutics 22, Nr. 12_Supplement (01.12.2023): C120. http://dx.doi.org/10.1158/1535-7163.targ-23-c120.
Der volle Inhalt der QuelleHong, Woojae, Jeon Hwang-Bo, Hyelin Jeon, Minsung Ko, Joongyeon Choi, Yong-Joon Jeong, Jae-Hyun Park et al. „A Comparative Study of the Hepatoprotective Effect of Centella asiatica Extract (CA-HE50) on Lipopolysaccharide/d-galactosamine-Induced Acute Liver Injury in C57BL/6 Mice“. Nutrients 13, Nr. 11 (15.11.2021): 4090. http://dx.doi.org/10.3390/nu13114090.
Der volle Inhalt der QuelleTanner, Berno, Dirk Hasenclever, Katja Stern, Wiebke Schormann, Martin Bezler, Matthias Hermes, Marc Brulport et al. „ErbB-3 Predicts Survival in Ovarian Cancer“. Journal of Clinical Oncology 24, Nr. 26 (10.09.2006): 4317–23. http://dx.doi.org/10.1200/jco.2005.04.8397.
Der volle Inhalt der QuelleLi, Zhuolin, Chengzhang Shang, Gao An, Chaoshe Guo, W. Frank An und Yi Yang. „Abstract 2619: A novel EGFR × HER3-targeting bispecific antibody drug-conjugate, BCG019, demonstrates robust anti-tumor efficacy in preclinical evaluation“. Cancer Research 84, Nr. 6_Supplement (22.03.2024): 2619. http://dx.doi.org/10.1158/1538-7445.am2024-2619.
Der volle Inhalt der QuelleCruz, Rodrigo G. B., Stephen F. Madden, Cathy E. Richards, Sri HariKrishna Vellanki, Hanne Jahns, Lance Hudson, Joanna Fay et al. „Human Epidermal Growth Factor Receptor-3 Expression Is Regulated at Transcriptional Level in Breast Cancer Settings by Junctional Adhesion Molecule-A via a Pathway Involving Beta-Catenin and FOXA1“. Cancers 13, Nr. 4 (19.02.2021): 871. http://dx.doi.org/10.3390/cancers13040871.
Der volle Inhalt der QuelleSatake, Tomoyuki, Chigusa Morizane, Mao Okada, Mariko Nishioka, Nobuyoshi Hiraoka, Satoshi Nara, Tomoya Kakegawa et al. „Abstract 3405: Changes in HER3 expression associated with chemotherapy for pancreatic cancer“. Cancer Research 83, Nr. 7_Supplement (04.04.2023): 3405. http://dx.doi.org/10.1158/1538-7445.am2023-3405.
Der volle Inhalt der QuelleLim, Malcolm, Tam H. Nguyen, Colleen Niland, Lynne E. Reid, Parmjit S. Jat, Jodi M. Saunus und Sunil R. Lakhani. „Landscape of Epidermal Growth Factor Receptor Heterodimers in Brain Metastases“. Cancers 14, Nr. 3 (21.01.2022): 533. http://dx.doi.org/10.3390/cancers14030533.
Der volle Inhalt der QuelleKurmasheva, Raushan, Peter Houghton, Vanessa Del Pozo, Samson Ghilu, Ryuichi Nakamura, Pang-Dian Fan, Emily Jocoy et al. „Abstract 1088: An evaluation of patritumab deruxtecan (HER3-DXd, U3-1402) against pediatric PDX models for hepatoblastoma and rhabdomyosarcoma - A report from the NCI PIVOT Program“. Cancer Research 84, Nr. 6_Supplement (22.03.2024): 1088. http://dx.doi.org/10.1158/1538-7445.am2024-1088.
Der volle Inhalt der QuelleBawa, I. Gusti Agung Gede, Sri Rahayu Santi, Wiwik Susanah Rita, Olan Suryanadi und Gek Indyan. „Active compounds of Michelia champaca bark extract against Curvularia verruculosa fungi causing leaf spot disease in rice (Oryza sativa L.)“. Journal of Applied and Natural Science 16, Nr. 1 (20.03.2024): 420–26. http://dx.doi.org/10.31018/jans.v16i1.5406.
Der volle Inhalt der QuelleRomaniello, Donatella, Ilaria Marrocco, Nishanth Belugali Nataraj, Irene Ferrer, Diana Drago-Garcia, Itay Vaknin, Roni Oren et al. „Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor“. Cancers 12, Nr. 9 (24.08.2020): 2394. http://dx.doi.org/10.3390/cancers12092394.
Der volle Inhalt der QuelleJacobs, Bart, Loredana Vecchione, Nicholas Hoe, Jef De Schutter, Bart Biesmans, Sharat Singh und Sabine Tejpar. „Effect of EGFR inhibition on HER3/PI3K activation by feedback induction of ErbB heterodimers in cetuximab-sensitive colon cancer cells.“ Journal of Clinical Oncology 31, Nr. 15_suppl (20.05.2013): 3626. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.3626.
Der volle Inhalt der QuellePark, Yeon Hee, Hyun Ae Jung, Won Jin Chang, Moon Ki Choi, Jung Yong Hong, Oh-Nam Ok, Jeong Ju Seo et al. „Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) patients who received taxane plus trastuzumab treatment.“ Journal of Clinical Oncology 31, Nr. 15_suppl (20.05.2013): 637. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.637.
Der volle Inhalt der QuelleKilroy, Mary K., Rosalin Mishra, Anastasia Stupecki, Wasim Feroz, Samar Alanazi und Joan T. Garrett. „Abstract 3988: The role of HER3 mutations in the progression of colon cancer and modulation of drug sensitivity and resistance“. Cancer Research 83, Nr. 7_Supplement (04.04.2023): 3988. http://dx.doi.org/10.1158/1538-7445.am2023-3988.
Der volle Inhalt der QuelleRathore, Moeez Ghani, Kimberly Curry, Christina Boutros, Zhenghe Wang, Jordan Winter und Rui Wang. „Abstract 3082: The liver microenvironment promotes glycolysis in metastatic colorectal cancer by activating her3“. Cancer Research 84, Nr. 6_Supplement (22.03.2024): 3082. http://dx.doi.org/10.1158/1538-7445.am2024-3082.
Der volle Inhalt der QuelleRaghav, Kanwal Pratap Singh, Takayuki Yoshino, Hiroya Taniguchi, Sabine Tejpar, Arndt Vogel, Zev A. Wainberg, Kensei Yamaguchi et al. „An open-label, phase II study of patritumab deruxtecan (HER3-DXd, U3-1402) in patients (pts) with previously treated advanced/metastatic colorectal cancer (CRC).“ Journal of Clinical Oncology 39, Nr. 3_suppl (20.01.2021): TPS157. http://dx.doi.org/10.1200/jco.2021.39.3_suppl.tps157.
Der volle Inhalt der QuelleKilroy, Mary K., Briley Park, Rosalin Mishra, Wasim Feroz, Cecilia Wischmeier und Joan T. Garrett. „Abstract 7150: Molecular insights into the oncogenic influence between mutant HER3, mutant KRAS, and their synergistic interplay in colorectal cancer pathogenesis“. Cancer Research 84, Nr. 6_Supplement (22.03.2024): 7150. http://dx.doi.org/10.1158/1538-7445.am2024-7150.
Der volle Inhalt der QuelleWang, Lina, Meijun Xiong, Xinju Gao, Chengang Zhou, Yu Han, Yanchun Li, Junhao Wang, Lili Shi, Gang Qin und Paul H. Song. „Abstract 2114: Enhancing therapeutic strategies for osimertinib-resistant EGFR-mutant NSCLC: A HER3 dual-payload ADC (dpADC) with topoisomerase I and EGFR tyrosine kinase inhibitor“. Cancer Research 84, Nr. 6_Supplement (22.03.2024): 2114. http://dx.doi.org/10.1158/1538-7445.am2024-2114.
Der volle Inhalt der QuelleBartsch, Rupert, Anna Sophie Berghoff, Zsuzsanna Bago-Horvath, Matthias Preusser, Guenther G. Steger, Margareta Rudas, Peter Birner und Christoph Zielinski. „Coexpression of HER3 as a predictor of survival in HER2-positve breast cancer patients.“ Journal of Clinical Oncology 31, Nr. 15_suppl (20.05.2013): 611. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.611.
Der volle Inhalt der QuelleAl-Akhrass, Hussein, James R. W. Conway, Annemarie Svane Aavild Poulsen, Ilkka Paatero, Jasmin Kaivola, Artur Padzik, Olav M. Andersen und Johanna Ivaska. „A feed-forward loop between SorLA and HER3 determines heregulin response and neratinib resistance“. Oncogene 40, Nr. 7 (08.01.2021): 1300–1317. http://dx.doi.org/10.1038/s41388-020-01604-5.
Der volle Inhalt der QuelleAlanazi, Samar M., Rosalin Mishra, Hima Patel, Mary K. Kilroy und Joan T. Garrett. „Abstract 5661: HER2 inhibition increases non-muscle myosin IIa to promote tumorigenesis in HER2+ breast cancers“. Cancer Research 82, Nr. 12_Supplement (15.06.2022): 5661. http://dx.doi.org/10.1158/1538-7445.am2022-5661.
Der volle Inhalt der QuelleBoutros, Christina S., Alexander W. Loftus, Moeez Rathore, Mehrdad Zarei, Kimberly Curry, Jordan M. Winter und Rui Wang. „Abstract 445: Determining the molecular and biologic effects of HER3 and IDH1 antagonism on liver endothelium-PDAC crosstalk“. Cancer Research 84, Nr. 6_Supplement (22.03.2024): 445. http://dx.doi.org/10.1158/1538-7445.am2024-445.
Der volle Inhalt der QuelleKojima, Yuki, Kazuki Sudo, Hiroshi Yoshida, Shu Yazaki, Momoko Tokura, Shosuke Kita, Kasumi Yamamoto et al. „Abstract 5083: Changes in HER3 expression profiles between initial diagnosis and recurrence in gynecologic cancers“. Cancer Research 82, Nr. 12_Supplement (15.06.2022): 5083. http://dx.doi.org/10.1158/1538-7445.am2022-5083.
Der volle Inhalt der Quelle